Clinical Trials · NCT05713578
Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study
- Phase
- EARLY_Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Enrollment
- 220
- Start date
- Mar 2023
- Locations
- 1 site, China
- Primary endpoint
- 3-year radiographic progression free survival (rPFS) rate